Smoking trajectories and residual cardiovascular risk in patients with stable coronary artery disease: an international cohort study
In stable CAD patients, smoking cessation is associated with significantly better CV outcomes and survival, irrespective of timing of cessation, and should therefore always be a priority. Smoking reduction was not associated with improved CV outcomes. Most former smokers quit within a year of CAD diagnosis, and CV risk increase with each subsequent year of active smoking.
Authors
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- Ian Ford (ORCID: https://orcid.org/0000-0001-5927-1823)
- Grégory Ducrocq (ORCID: https://orcid.org/0000-0003-4069-1128)
- Nicolas Danchin (ORCID: https://orcid.org/0000-0001-9263-5051)
- Keith A.A. Fox (ORCID: https://orcid.org/0000-0002-0140-2752)
- Jean‐Claude Tardif (ORCID: https://orcid.org/0000-0002-8200-8983)
- Laurent J. Feldman (ORCID: https://orcid.org/0000-0003-2626-703X)
- Michał Tendera (ORCID: https://orcid.org/0000-0002-0812-6113)
- Jules Mesnier (ORCID: https://orcid.org/0000-0002-2131-6763)
- Louis Giovachini (ORCID: https://orcid.org/0009-0003-3562-813X)
- Roberto Ferrari (ORCID: https://orcid.org/0000-0003-2046-9175)
- Emmanuelle Vidal‐Petiot
Institutions
- Medical University of Silesia (PL)
- University of Ferrara (IT)
- Université Paris Cité (FR)
- Montreal Heart Institute (CA)
- Royal Brompton Hospital (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Maria Cecilia Hospital (IT)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Européen (FR)
- Institut de Médecine et d'Epidémiologie Africaines (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Alliance nationale pour les sciences de la vie et de la santé (FR)
- Digital Research Alliance of Canada
- Université de Montréal (CA)
- University of Glasgow (GB)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1093/eurjpc/zwaf222
- Citations
- 3
- Primary Topic
- Cardiovascular Disease and Adiposity
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Boston Scientific Corporation
- Amarin Corporation
- Kowa Company
- TauRx Pharmaceuticals
- Novo Nordisk
- Servier
- Esperion Therapeutics